Australia's largest stock trading and investment forum Australia's #1 stock forum

The fact they can’t raise after FDA is pretty frightening. Why...

First 685 Last

Share
Profile

Follow
ckchristian

2,455 Posts.

400

17/04/24

13:02

Post #: 73386872
Share

Originally posted by green8: ↑

A very disappointing update.
N.L is commercially underperforming and well behind expectations.

Imo the company needs change and change should start at the top.

Staff were released until we got additional capital which appears to be impacting our growth.
The cap raise has been fumbled for almost a year and still not complete.
A.I. and Med Tech are the 'flavour of the month' sectors and raising funds in this area should be straight forward, especially for a company with presence in USA, EU & Asia.
Playing around with retail aussie brokers isn't the way to go imo. The money raised recently costs us 15% p.a -plus- likely dilution. This smells of desperation.

Imo we need immediate change to avoid large dilution or potentially going under.

Expand

The fact they can’t raise after FDA is pretty frightening.

Why isn't Philips implementing Strokeviewer into the thousands of hospitals in the US that Philips are already contracted to? It's a perfect add on product for them.

Either the product is shit or the people are useless.

I believe it is the latter.
2 Upvote

Reply

There are more pages in this discussion • 1 more message in this thread...

First 685 Last